HomeTRVN • NASDAQ
Trevena Inc
$0.46
After Hours:
$0.46
(0.89%)-0.0041
Closed: Mar 28, 8:00:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$0.46
Day range
$0.45 - $0.49
Year range
$0.41 - $3.28
Market cap
8.40M USD
Avg Volume
148.88K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2023Y/Y change
Revenue
180.00K141.10%
Operating expense
8.83M-31.79%
Net income
-7.93M48.15%
Net profit margin
-4.41K-226.16%
Earnings per share
EBITDA
-8.74M44.19%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2023Y/Y change
Cash and short-term investments
34.95M-13.47%
Total assets
45.13M-11.54%
Total liabilities
41.58M42.63%
Total equity
3.55M
Shares outstanding
15.17M
Price to book
1.91
Return on assets
-52.55%
Return on capital
-64.22%
Net change in cash
(USD)Sep 2023Y/Y change
Net income
-7.93M48.15%
Cash from operations
-8.93M15.84%
Cash from investing
0.00-100.00%
Cash from financing
15.78M1,334.64%
Net change in cash
6.86M175.52%
Free cash flow
-6.58M-17.02%
About
Trevena Inc is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Founded
2007
Employees
35
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu